

# Eric Charles LaCasse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8300401/publications.pdf>

Version: 2024-02-01

46  
papers

4,790  
citations

172386

29  
h-index

223716

46  
g-index

46  
all docs

46  
docs citations

46  
times ranked

5526  
citing authors

#	ARTICLE	IF	CITATIONS
1	The inhibitors of apoptosis (IAPs) and their emerging role in cancer. <i>Oncogene</i> , 1998, 17, 3247-3259.	2.6	920
2	The inhibitors of apoptosis (IAPs) as cancer targets. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 1543-1568.	2.2	506
3	IAP-targeted therapies for cancer. <i>Oncogene</i> , 2008, 27, 6252-6275.	2.6	455
4	Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1999, 264, 781-788.	1.0	319
5	Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic acid-binding proteins. <i>Nucleic Acids Research</i> , 1995, 23, 1647-1656.	6.5	211
6	Inhibitor of Apoptosis Protein cIAP2 Is Essential for Lipopolysaccharide-Induced Macrophage Survival. <i>Molecular and Cellular Biology</i> , 2006, 26, 699-708.	1.1	182
7	Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. <i>Clinical Cancer Research</i> , 2003, 9, 2826-36.	3.2	175
8	Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. <i>Oncogene</i> , 2004, 23, 8105-8117.	2.6	165
9	Baculoviral IAP Repeat-Containing-4 Protects Optic Nerve Axons in a Rat Glaucoma Model. <i>Molecular Therapy</i> , 2002, 5, 780-787.	3.7	151
10	Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis. <i>Clinical Cancer Research</i> , 2006, 12, 5231-5241.	3.2	136
11	Modulation of immune signalling by inhibitors of apoptosis. <i>Trends in Immunology</i> , 2012, 33, 535-545.	2.9	125
12	Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4741-4746.	0.8	115
13	Smac mimetics and innate immune stimuli synergize to promote tumor death. <i>Nature Biotechnology</i> , 2014, 32, 182-190.	9.4	104
14	Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. <i>Nature Communications</i> , 2017, 8, .	5.8	103
15	Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. <i>Trends in Molecular Medicine</i> , 2014, 20, 652-665.	3.5	96
16	Recruitment of Octamer Transcription Factors to DNA by Glucocorticoid Receptor. <i>Molecular and Cellular Biology</i> , 1998, 18, 3416-3430.	1.1	89
17	Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1660-1666.	0.8	88
18	XIAP Protection of Photoreceptors in Animal Models of Retinitis Pigmentosa. <i>PLoS ONE</i> , 2007, 2, e314.	1.1	73

#	ARTICLE	IF	CITATIONS
19	Down-regulation of c-FLIP Enhances Death of Cancer Cells by Smac Mimetic Compound. <i>Cancer Research</i> , 2009, 69, 7729-7738.	0.4	68
20	TWEAK and cIAP1 Regulate Myoblast Fusion Through the Noncanonical NF- $\kappa$ B Signaling Pathway. <i>Science Signaling</i> , 2012, 5, ra75.	1.6	66
21	Spurious splicing within the XIAP 5' UTR occurs in the Rluc/Fluc but not the $\hat{A}$ gal/CAT bicistronic reporter system. <i>Rna</i> , 2005, 11, 1605-1609.	1.6	57
22	Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/GEM(R)640. <i>Annals of the New York Academy of Sciences</i> , 2005, 1058, 215-234.	1.8	56
23	Downregulation of XIAP expression in ovarian cancer cells induces cell death <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2008, 122, 1430-1434.	2.3	50
24	ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 37383-37392.	1.6	49
25	Role of the TWEAK-Fn14-cIAP1-NF- $\kappa$ B Signaling Axis in the Regulation of Myogenesis and Muscle Homeostasis. <i>Frontiers in Immunology</i> , 2014, 5, 34.	2.2	44
26	Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. <i>Cancer Letters</i> , 2013, 332, 215-224.	3.2	41
27	SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. <i>Science Signaling</i> , 2020, 13, .	1.6	34
28	X-Linked Inhibitor of Apoptosis Antagonism: Strategies in Cancer Treatment. <i>Clinical Cancer Research</i> , 2006, 12, 3238-3242.	3.2	33
29	The role of XAF1 in cancer. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 469-76.	2.3	33
30	Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization. <i>PLoS ONE</i> , 2018, 13, e0193643.	1.1	27
31	Distinct Role of Calmodulin and Calmodulin-dependent Protein Kinase-II in Lipopolysaccharide and Tumor Necrosis Factor- $\alpha$ -mediated Suppression of Apoptosis and Antiapoptotic c-IAP2 Gene Expression in Human Monocytic Cells*. <i>Journal of Biological Chemistry</i> , 2005, 280, 37536-37546.	1.6	26
32	How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease. <i>Genetics in Medicine</i> , 2017, 19, 133-143.	1.1	26
33	X-linked Inhibitor of Apoptosis Regulates T Cell Effector Function. <i>Journal of Immunology</i> , 2007, 179, 7553-7560.	0.4	25
34	Targeted ablation of the cellular inhibitor of apoptosis 1 (cIAP1) attenuates denervation-induced skeletal muscle atrophy. <i>Skeletal Muscle</i> , 2019, 9, 13.	1.9	24
35	Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. <i>Oncotarget</i> , 2017, 8, 3495-3508.	0.8	22
36	Combination of IAP Antagonists and TNF- $\alpha$ -Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression. <i>Molecular Therapy - Oncolytics</i> , 2018, 10, 28-39.	2.0	19

#	ARTICLE	IF	CITATIONS
37	Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists. <i>International Journal of Developmental Biology</i> , 2015, 59, 141-147.	0.3	17
38	Loss of cIAP1 attenuates soleus muscle pathology and improves diaphragm function in mdx mice. <i>Human Molecular Genetics</i> , 2013, 22, 867-878.	1.4	14
39	Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. <i>Oncoimmunology</i> , 2014, 3, e28541.	2.1	12
40	Microsomal dexamethasone binding sites identified by affinity labelling. <i>The Journal of Steroid Biochemistry</i> , 1990, 35, 47-54.	1.3	9
41	The transcription factor SP3 drives TNF- $\hat{\pm}$ expression in response to Smac mimetics. <i>Science Signaling</i> , 2019, 12, .	1.6	9
42	Nuclear and nuclear envelope binding proteins of the glucocorticoid receptor nuclear localization peptide identified by crosslinking. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1991, 40, 279-285.	1.2	8
43	Sp3-cificity of TNF- $\hat{\pm}$ expression promotes the Smac mimetic-mediated killing of cancer cells. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1607456.	0.3	3
44	Evidence for Apoptosis in the Fetal Down Syndrome Brain. <i>Journal of Child Neurology</i> , 2001, 16, 438.	0.7	3
45	The inhibitors of apoptosis (IAPs): Over 20 years of research into life and death. <i>Seminars in Cell and Developmental Biology</i> , 2015, 39, 70-71.	2.3	1
46	Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?. <i>Cell Death and Disease</i> , 2020, 11, 350.	2.7	1